Abstract
Brain injury constitutes a disabling health condition of several etiologies. One of the major causes of brain injury is hypoxia-ischemia. Until recently, pharmacological treatments were solely focused on neurons. In the last decades, glial cells started to be considered as alternative targets for neuroprotection. Novel treatments for hypoxia-ischemia intend to modulate reactive forms of glial cells, and/or potentiate their recovery response. In this review, we summarize these neuroprotective strategies in hypoxia-ischemia and discuss their mechanisms of action.
Keywords: brain injury, hypoxia-ischemia, pharmacological treatments, glial cells, neuroprotection
Current Pharmaceutical Design
Title:Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells
Volume: 23 Issue: 26
Author(s): Maria Ines Herrera*, Sofia Mucci*, George E. Barreto, Rodolfo Kolliker-Frers and Francisco Capani*
Affiliation:
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
Keywords: brain injury, hypoxia-ischemia, pharmacological treatments, glial cells, neuroprotection
Abstract: Brain injury constitutes a disabling health condition of several etiologies. One of the major causes of brain injury is hypoxia-ischemia. Until recently, pharmacological treatments were solely focused on neurons. In the last decades, glial cells started to be considered as alternative targets for neuroprotection. Novel treatments for hypoxia-ischemia intend to modulate reactive forms of glial cells, and/or potentiate their recovery response. In this review, we summarize these neuroprotective strategies in hypoxia-ischemia and discuss their mechanisms of action.
Export Options
About this article
Cite this article as:
Herrera Ines Maria *, Mucci Sofia*, Barreto E. George, Kolliker-Frers Rodolfo and Capani Francisco *, Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells, Current Pharmaceutical Design 2017; 23 (26) . https://dx.doi.org/10.2174/1381612823666170727145422
| DOI https://dx.doi.org/10.2174/1381612823666170727145422 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Medicinal Chemistry Perspective of Fused Isoxazole Derivatives
Current Topics in Medicinal Chemistry The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews Ischemic Tolerance Induced by Normobaric Hyperoxia and Evaluation of Group I and II Metabotropic Glutamate Receptors
Current Neurovascular Research The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets A Review of Agents Patented for their Neuroprotective Properties
Recent Patents on CNS Drug Discovery (Discontinued) Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design Current and Future Therapeutic Strategies for Parkinsons Disease
Current Pharmaceutical Design Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Estrogen and Serotonin: Complexity of Interactions and Implications for Epileptic Seizures and Epileptogenesis
Current Neuropharmacology Efficient Synthesis and Spectroscopic Characterization of Biologically Relevant Pregnane Derivatives, and its Glycoside
Current Chinese Chemistry The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology Effect of Hypoxia on Cytochrome P450 Activity and Expression
Current Drug Metabolism Flavonoids Health Benefits and Their Molecular Mechanism
Mini-Reviews in Medicinal Chemistry Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry

